{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:27:41Z","timestamp":1793500061453,"version":"4.5.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>While prior research has shown differences in the risk of malaria infection and sickness between males and females, little is known about sex differences in vaccine-induced immunity to malaria. Identifying such differences could elucidate important aspects of malaria biology and facilitate development of improved approaches to malaria vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using a standardized enzyme-linked immunosorbent assay, IgG antibodies to the major surface protein on <jats:italic>Plasmodium falciparum<\/jats:italic> (Pf) sporozoites (SPZ), the Pf circumsporozoite protein (PfCSP), were measured before and two weeks after administration of a PfSPZ-based malaria vaccine (PfSPZ Vaccine) to 5-month to 61-year-olds in 11 clinical trials in Germany, the US and five countries in Africa, to determine if there were differences in vaccine elicited antibody response between males and females and if these differences were associated with differential protection against naturally transmitted Pf malaria (Africa) or controlled human malaria infection (Germany, the US and Africa).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Females \u2265 11 years of age made significantly higher levels of antibodies to PfCSP than did males in most trials, while there was no indication of such differences in infants or children. Although adult females had higher levels of antibodies, there was no evidence of improved protection compared to males. In 2 of the 7 trials with sufficient data, protected males had significantly higher levels of antibodies than unprotected males, and in 3 other trials protected females had higher levels of antibodies than did unprotected females.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Immunization with PfSPZ Vaccine induced higher levels of antibodies in post-pubertal females but showed equivalent protection in males and females. We conclude that the increased antibody levels in post-pubertal females did not contribute substantially to improved protection. We hypothesize that while antibodies to PfCSP (and PfSPZ) may potentially contribute directly to protection, they primarily correlate with other, potentially protective immune mechanisms, such as antibody dependent and antibody independent cellular responses in the liver.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1006716","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T10:49:00Z","timestamp":1666694940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy"],"prefix":"10.3389","volume":"13","author":[{"given":"Natasha","family":"KC","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. W. Preston","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Riyahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumana","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten E.","family":"Lyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mordm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamadou S.","family":"Sissoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said A.","family":"Jongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente Urbano Nsue Ndong","family":"Nchama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxmillian","family":"Mpina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Steinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Oneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingLin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Murshedkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"B1","volume-title":"World malaria report 2021","year":"2021"},{"key":"B2","volume-title":"Malaria eradication: benefits, future scenarios and feasibility. executive summary","year":"2019"},{"key":"B3","unstructured":"Data, Sub-Saharan Africa"},{"key":"B4","unstructured":"WHO calls for reinvigorated action to fight malaria (News release)2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.4269\/ajtmh.21-0899","article-title":"Relative burdens of the COVID-19, malaria, tuberculosis, and HIV\/AIDS epidemics in sub-Saharan Africa","volume":"105","author":"Bell","year":"2021","journal-title":"Am J Trop Med Hygiene"},{"key":"B6","unstructured":"WHO recommends groundbreaking malaria vaccine for children at risk2021"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2015.09.011","article-title":"The march toward malaria vaccines","volume":"49","author":"Hoffman","year":"2015","journal-title":"Am J Prev Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.1211548","article-title":"Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity","volume":"334","author":"Epstein","year":"2011","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-015-0817-x","article-title":"Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved plasmodium falciparum sporozoites in malaria-na\u00efve volunteers: effect of injection volume and dose on infectivity rates","volume":"14","author":"G\u00f3mez-P\u00e9rez","year":"2015","journal-title":"Malar J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12936-015-0628-0","article-title":"Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres","volume":"14","author":"Mordm\u00fcller","year":"2015","journal-title":"Malar J"},{"key":"B12","author":"Mordm\u00fcller","year":""},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against plasmodium falciparum malaria by PfSPZ vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1615324114","article-title":"Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection","volume":"114","author":"Lyke","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ vaccine against plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-1014","article-title":"Safety, immunogenicity, and protective efficacy against controlled human malaria infection of plasmodium falciparum sporozoite vaccine in Tanzanian adults","volume":"99","author":"Jongo","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0449","article-title":"Advancing global health through development and clinical trials partnerships: A randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of plasmodium falciparum sporozoites vaccine for malaria in healthy equatoguinean men","volume":"98","author":"Olotu","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0835","article-title":"Safety and differential antibody and T-cell responses to the plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in Tanzanian adults, adolescents, children, and infants","volume":"100","author":"Jongo","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz925","article-title":"Safety, tolerability, and immunogenicity of PfSPZ vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya","volume":"71","author":"Steinhardt","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5629","article-title":"A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1","volume":"12","author":"Roestenberg","year":"2020","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1152","article-title":"Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian adults","volume":"71","author":"Jongo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1294","article-title":"Multidose priming and delayed boosting improve PfSPZ vaccine efficacy against heterologous p. falciparum controlled human malaria infection","volume":"73","author":"Lyke","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0435","article-title":"Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in equatoguinean adults","volume":"104","author":"Jongo","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","author":"Oneko","year":"2021","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.21-0942","article-title":"Multi-dose priming regimens of PfSPZ vaccine: Safety and efficacy against controlled human malaria infection in equatoguinean adults","volume":"106","author":"Jongo","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00332-7","article-title":"Safety and efficacy of a three-dose regimen of plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial","volume":"22","author":"Sissoko","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-022-00510-z","article-title":"Identification of a PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection \u2013 a randomized controlled trial","volume":"7","author":"Mordm\u00fcller","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B29","article-title":"A randomized controlled trial showing safety and durable efficacy of a whole sporozoite vaccine against endemic malaria science translational medicine","author":"Sirima","year":"2022"},{"key":"B30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-015-0817-x","article-title":"Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates","volume":"14","author":"Gomez-Perez","year":"2015","journal-title":"Malar J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005374","article-title":"SeXX matters in infectious disease pathogenesis","volume":"12","author":"vom Steeg","year":"2016","journal-title":"PLoS Pathog"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.78.878","article-title":"Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value","volume":"78","author":"Sanderson","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.054","article-title":"Sexual dimorphism of humoral immunity with human vaccines","volume":"26","author":"Cook","year":"2008","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.513","article-title":"Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses","volume":"168","author":"Engler","year":"2008","journal-title":"Arch Intern Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1805268115","article-title":"Biological sex affects vaccine efficacy and protection against influenza in mice","volume":"115","author":"Fink","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Mordmuller","year":"2017","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"Borenstein","year":"2009"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/eb-2017-102753","article-title":"Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article","volume":"20","author":"Chaimani","year":"2017","journal-title":"Evid Based Ment Health"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.05.008","article-title":"Feasibility of direct venous inoculation of the radiation-attenuated plasmodium falciparum whole sporozoite vaccine in children and infants in siaya, western Kenya","volume":"38","author":"Oneko","year":"2020","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The xs and y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1604570113","article-title":"Community deworming alleviates geohelminth-induced immune hyporesponsiveness","volume":"113","author":"Wammes","year":"2016","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1006716\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T11:48:21Z","timestamp":1678708101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1006716\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2022.1006716"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1006716","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"article-number":"1006716"}}